Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 3:8:73-4.
doi: 10.2174/1874364101408010073. eCollection 2014.

LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines

R Moosavi  1 , F Bremner  1 , J Acheson  1
Affiliations

LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines

R Moosavi et al. Open Ophthalmol J. .

Abstract

We report adherence to United Kingdom national guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for FAME surveillance. 38 patients in total were seen, representing 9% of all new ophthalmic referrals during the study period. 26% were seen between 2 and 4 months after starting Fingolimod treatment, 74% between 3 and 4 months after starting Fingolimod treatment. The impact on clinical services is discussed.

Keywords: Fingolimod; guidelines; macular oedema; screening..

PubMed Disclaimer

References

    1. Cohen J, Jeffrey AC, Frederik B, Giancarlo C , et al. Oral fingoli-mod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15. - PubMed
    1. Jeffrey AC, Frederik B, Giancarlo C , et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. - PubMed
    1. NICE Final appraisal determination - Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. Author: Ken Stein Vice Chair Appraisal Committee NICE (ID63) March 2012 Available from URL http://guidance.nice.org.uk/TA/Wave20/71.
    1. European Medicines Agency SmPC for Gilenya : EPAR Product Information - Gilenya -EMEA/H/C/002202 -PSUV/0023 - Section 44. March 2011 Avaliable from URL: http://www.ema.europa.e u/docs/en_GB/document_library/EPAR_-_Product_Information/hu man/002202/WC500104528.pdf.
    1. National Institute for Health and Care Excellence Guidelines. https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NI....